Back to Feed
总结
诺和诺德（Novo Nordisk）据报道在美国推出其首款用于肥胖治疗的GLP-1口服减重药，并以更具竞争力的定价策略推动市场“价格战”，试图在与礼来等同类药物竞争中扩大患者覆盖、提升医保与渠道谈判筹码。多家媒体称该药已进入药房销售，并承诺供应充足，以降低注射剂型门槛并减少此前紧缺带来的配给。业内预计，口服剂型普及将改变处方与支付格局，但降价也可能压缩行业利润、加速2026年减重药物市场洗牌。
正文
Novo Nordisk launches price war over weight-loss pills Financial Times First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. CNBC A Pill Version of Wegovy Hits Pharmacies Time Magazine What to watch for in weight loss drugs in 2026: Price changes, GLP-1 pills and more NBC News The first GLP-1 weight-loss pill is now available, with pledge of abundant supply The Washington Post
发布时间：